CCOP - Michigan Cancer Research Consortium
Claim this profile,
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Prostate Cancer
355 reported clinical trials
38 medical researchers
Summary
CCOP - Michigan Cancer Research Consortium is a medical facility located in undefined, undefined. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Recurrence, Prostate Cancer and other specialties. CCOP - Michigan Cancer Research Consortium is involved with conducting 355 clinical trials across 378 conditions. There are 38 research doctors associated with this hospital, such as Tareq Al Baghdadi, Elie G. Dib, Samir Narayan, and Paul Swiecicki.Area of expertise
1Breast Cancer
Global LeaderER positive
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
70 reported clinical trials
127 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
34 reported clinical trials
94 drugs studied
Samir NarayanSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Cancer
Studies Prostate Cancer
26 reported clinical trials
70 drugs studied
Paul SwiecickiUniversity of Michigan Comprehensive Cancer Center1 year of reported clinical research
Expert in Cancer
Studies Squamous Cell Carcinoma
19 reported clinical trials
29 drugs studied
Clinical Trials running at CCOP - Michigan Cancer Research Consortium
Prostate Cancer
Cancer
Breast Cancer
Liver Cancer
Tumors
Hepatocellular Carcinoma
Glioblastoma
Renal Cell Carcinoma
Oropharyngeal Cancer
Squamous Cell Carcinoma
Combination Therapy
for Metastatic Prostate Cancer
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer. This is a phase 2 study to deliver focal radiation with pulsed systemic therapy of Abiraterone, ADT and Lynparza (olaparib) in men with castration sensitive oligometastatic prostate cancer.
Recruiting3 awards Phase 2
Moderate vs Ultra-Hypofractionated Radiation
for Prostate Cancer
This trial compares the quality of life of prostate cancer patients treated with a short-term, high-dose radiation therapy to those treated with the standard, longer-term radiation therapy. The new method aims to reduce the number of treatments, making it easier for patients to complete their treatment and potentially improve their quality of life. This newer radiotherapy method for prostate cancer aims to shorten the treatment duration and improve patient convenience.
Recruiting1 award Phase 2
Talazoparib + Belinostat
for Metastatic Cancer
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.
Recruiting1 award Phase 114 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at CCOP - Michigan Cancer Research Consortium?
CCOP - Michigan Cancer Research Consortium is a medical facility located in undefined, undefined. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Recurrence, Prostate Cancer and other specialties. CCOP - Michigan Cancer Research Consortium is involved with conducting 355 clinical trials across 378 conditions. There are 38 research doctors associated with this hospital, such as Tareq Al Baghdadi, Elie G. Dib, Samir Narayan, and Paul Swiecicki.